Prostate Cancer
Conditions
Keywords
prostate cancer, primary, recurrence, F-18-FCH PET/CT, Ga-68-NODAGA-MJ9 PET/CT
Brief summary
Prostate cancer patients for whom a F-18-FCH PET/CT is indicated. Ga-68-NODAGA-MJ9 is a new PET/CT radiotracer aiming at giving complementary information : more precise images and early localisation of recurrence to standard imaging
Detailed description
Patient with primary or relapsing prostate cancer for whom F-18-FCH PET/CT is indicated will be proposed to participate to the present study. After signing the patient informed consent, both F-18-FCH and Ga-68-NODAGA-MJ9 PET/CT will be scheduled with a maximum 10 day-interval. No adverse events are expected.
Interventions
DIAGNOSTIC_TEST1 PET/CT with F-18-FCH + 1 PET/CT with Ga-68-NODAGA-MJ9
Each patient will have two PET/CT
Sponsors
University of Lausanne Hospitals
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age : adult patients * Karnofsky : ≥ 80% * Patients with histologically proven prostate cancer for whom 18F-fluocholine PET/CT is indicated for primary cancer staging, or for recurrence with increase of blood PSA. In order to provide a detection probability of 30% or more, a blood PSA 0.5 ng / ml or more in post initial curative intent surgery will be required. * Signed informed consent.
Exclusion criteria
* Lack of discernment to sign the consent form * Age \<18 years * Patient under hormonal treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Positivity of the new radiotracer Ga-68-NODAGA-MJ9 compared to the standard radiotracer F-18-FCH | At baseline (after F-18-FCH PET/CT) | PET images : SUVmax, SUVmean, VOI (mL), SUV41% lesions/ SUVbackground CT images : size lesions measured in 3D (axial, coronal and sagittal), density in Hounsfield Units (HU) |
Countries
Switzerland
Outcome results
None listed